Mounjaro (Tirzepatide): A1C Drop 2.6% + 22% Weight Loss (Better Than Ozempic?)

”

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or qualified health provider with any questions you may have regarding a medical condition.

In 2022, a new diabetes medication arrived with results that stunned the medical community: tirzepatide (Mounjaro).

In clinical trials, it lowered A1C by up to 2.6% and caused weight loss of up to 22%—more than any diabetes medication before it.

What makes tirzepatide different? It's a dual agonist, activating not one but two hormone systems. The 2025 ADA guidelines recognize it as a first-line option for patients with type 2 diabetes and high weight concerns.

What Is Tirzepatide?

The First-in-Class Medication

Tirzepatide is the first medication in a new class: dual GIP/GLP-1 receptor agonists.

Component	Action	Effect
GLP-1 agonism	Stimulates GLP-1 receptors	Increases insulin, reduces glucagon, slows emptying, increases fullness
GIP agonism	Stimulates GIP receptors	Increases insulin, may improve fat metabolism, additive to GLP-1

Why Target Two Hormones?

GLP-1 alone (Ozempic, Trulicity) is effective, but tirzepatide's dual action appears to be more effective than GLP-1 alone:

Outcome	GLP-1 Alone	Tirzepatide (Dual)
A1C reduction	1.0-1.8%	1.8-2.6%
Weight loss	5-15%	15-22%

How Tirzepatide Works

The Mechanisms

Mechanism	Effect on Body
Increases insulin secretion	Glucose-dependent (more insulin when blood sugar high)
Decreases glucagon secretion	Reduces liver glucose production
Slows gastric emptying	Increases fullness after meals
Acts on hypothalamus	Reduces appetite, increases satiety
Improves insulin sensitivity	May enhance fat metabolism
Increases energy expenditure	Possible GIP effect

Why GIP Matters

GIP (glucose-dependent insulinotropic polypeptide) is a gut hormone with complex effects:

Traditional View	Emerging Understanding
"Inert" in diabetes	Active and synergistic with GLP-1
May cause weight gain	Tirzepatide causes significant weight loss
Unclear role	GIP + GLP-1 = greater than GLP-1 alone

Key insight: GIP may enhance the metabolic benefits of GLP-1, particularly for weight loss.

Clinical Trial Results

SURPASS Trials Program

The SURPASS program compared tirzepatide to other diabetes medications:

Trial	Comparison	Tirzepatide Results
SURPASS-1	Placebo (early diabetes)	A1C reduction 1.8-2.6%
SURPASS-2	Semaglutide 1 mg	A1C reduction 2.0% vs 1.9% (semaglutide)
SURPASS-3	Basal-bolus insulin	A1C reduction 2.1% vs 1.2% (insulin)
SURPASS-4	Basal insulin + prandial	A1C reduction 2.3% vs 1.9% (insulin)
SURPASS-5	Placebo (after insulin)	A1C reduction 2.0%

Weight Loss Results

Trial	Tirzepatide Weight Loss	Comparison
SURPASS-2	-7.6 kg (5 mg) to -12.9 kg (15 mg)	Semaglutide: -6.2 kg
SURPASS-3	-7.5 kg (5 mg) to -12.0 kg (15 mg)	Insulin: +2.2 kg (gain)

At the 15 mg dose:

Average weight loss: 15-22%
89% of patients lost ≥ 5% body weight
57% lost ≥ 15% body weight
30% lost ≥ 20% body weight

FDA Indications and Dosing

FDA Approval

Indication	Details
Type 2 diabetes	Approved May 2022
Weight management	Under review (expected 2023/2024)

Available Doses

Dose	Use	A1C Reduction	Weight Loss
2.5 mg	Starting dose	~1.2%	~3-5%
5 mg	Therapeutic dose	~1.7%	~7-10%
7.5 mg	Therapeutic dose	~1.9%	~10-12%
10 mg	Therapeutic dose	~2.0%	~12-15%
12.5 mg	Therapeutic dose	~2.2%	~15-18%
15 mg	Maximum dose	~2.6%	~15-22%

Titration Schedule

Week	Dose
Weeks 1-4	2.5 mg weekly
Weeks 5-8	5 mg weekly
Every 4 weeks	Increase by 2.5 mg if needed

Start at 2.5 mg to minimize GI side effects. The 2.5 mg dose is primarily for titration—it has minimal glucose-lowering effect.

Side Effects

Common Side Effects

Side Effect	Frequency	Notes
Nausea	10-25%	Dose-dependent; improves over time
Vomiting	5-10%	Usually during titration
Diarrhea	5-10%	Usually mild
Abdominal pain	5-8%	Upper abdominal
Decreased appetite	5-10%	Actually helps weight loss
Constipation	3-5%	Manage with fiber/fluids
Injection site reactions	2-5%	Redness, itching

Managing GI Side Effects

Strategy	How
Start low, go slow	Use 4-week titration intervals
Eat smaller meals	Especially during titration
Avoid high-fat foods	Can worsen nausea
Stay hydrated	Important if vomiting/diarrhea
Time your dose	Take on same day each week
Be patient	Side effects typically improve 4-8 weeks after each dose increase

Serious but Rare Side Effects

Concern	Risk	Monitoring
Pancreatitis	Very rare	Prompt evaluation of severe abdominal pain
Gallbladder disease	Slightly increased	Be aware of symptoms
Medullary thyroid cancer	Theoretical (animal data)	Avoid if personal/family history
Hypoglycemia	Risk increased with insulin/sulfonylureas	May need to reduce other medications

Tirzepatide vs. Other Medications

Compared to Semaglutide (Ozempic)

Feature	Tirzepatide	Semaglutide
A1C reduction	2.0-2.6%	1.0-1.8%
Weight loss	15-22%	5-15%
Convenience	Weekly injection	Weekly injection
Side effects	Similar profile	Similar profile
Cost	Similar (~$1000/month)	Similar (~$1000/month)
Cardiovascular outcome	Ongoing trial	Proven benefit

Compared to Insulin

Feature	Tirzepatide	Basal-Bolus Insulin
A1C reduction	Greater	Slightly less
Weight loss	15-22% loss	2-5 kg gain
Hypoglycemia risk	Low	Significant
Convenience	1 weekly injection	2-4+ injections daily
Cost	High	Variable (often lower)

Compared to Other Weight Loss Medications

Medication	Weight Loss	Diabetes Benefit
Tirzepatide	15-22%	Yes, primary indication
Semaglutide 2.4 mg (Wegovy)	12-15%	Yes (Ozempic 1 mg)
Liraglutide 3 mg (Saxenda)	5-10%	Yes (Victoza 1.8 mg)
Phentermine/topiramate	5-10%	No
Bupropion/naltrexone	3-5%	No

Who Should Consider Tirzepatide?

Ideal Candidates

The 2025 ADA guidelines recommend tirzepatide as a first-line option (with metformin) for patients with:

Characteristic	Why Tirzepatide
BMI ≥ 30 OR BMI ≥ 27 with comorbidity	Significant weight loss benefit
High A1C (≥ 9%)	Potent glucose-lowering
Need for both glucose and weight management	Dual benefit
Cardiovascular risk	Positive CV outcome trial results
Established CVD	Alternative to GLP-1 with CV benefit

Consider Tirzepatide If You:

Have tried other medications without reaching A1C goal
Need significant weight loss for health reasons
Have high cardiovascular risk
Want to minimize diabetes medications (one injection vs multiple pills)
Can afford the cost (or have insurance coverage)

Cost and Access

Pricing

Item	Approximate Cost
Mounjaro (tirzepatide)	$900-$1,200/month
Manufacturer savings card	May reduce to as low as $25 for eligible patients

Insurance Coverage

Most Medicare Part D plans cover Mounjaro for type 2 diabetes
Commercial insurance coverage varies
Prior authorization often required
Step therapy may apply (try metformin first)

Patient Assistance

Eli Lilly offers:

Mounjaro Savings Card for commercially insured patients
Lilly Cares for uninsured/underinsured patients who qualify

Practical Considerations

Administration

Weekly subcutaneous injection (abdomen, thigh, or upper arm)
Same day each week (pick a memorable day)
Can be taken with or without food
Does not require timing with meals (unlike some diabetes medications)

Storage

Condition	Storage
Unopened pens	Refrigerate (36-46°F) until expiration
Opened pens	Room temperature or refrigerated for up to 30 days
Extreme temperatures	Avoid (don't leave in hot car or freeze)

Missed Dose

If within 4 days of scheduled dose: Take as soon as remembered
If more than 4 days: Skip and take next scheduled dose
Return to regular schedule at next injection day

Future of Tirzepatide

Potential Future Indications

Indication	Status
Weight management (obesity)	Under FDA review (SURMOUNT trials)
Obstructive sleep apnea	Being studied
Heart failure	Early trials underway
NASH (fatty liver disease)	Being studied

SURMOUNT Trials (Weight Management)

Trial	Status	Results So Far
SURMOUNT-1	Completed	16% weight loss at 72 weeks
SURMOUNT-2	Completed	15% weight loss vs 2% placebo
SURMOUNT-3	Completed	16% weight loss (intensive lifestyle intervention)
SURMOUNT-4	Ongoing	Maintenance after weight loss
SURMOUNT-5	Ongoing	Long-term efficacy/safety

Key Takeaways

Tirzepatide is a dual GIP/GLP-1 agonist—first in its class
Lowers A1C by up to 2.6%—more than any other diabetes medication
Causes 15-22% weight loss—more than most bariatric surgery results
Administered as weekly injection at doses from 2.5 to 15 mg
Side effects mostly GI and improve over time
First-line option for patients with high BMI and type 2 diabetes
Expensive but manufacturer assistance programs available

FAQ Section

What is tirzepatide used for?

Tirzepatide (Mounjaro) is FDA-approved for treating type 2 diabetes. It lowers blood sugar by activating both GIP and GLP-1 receptors. It's also being studied for weight management, with potential FDA approval for obesity.

Is Mounjaro better than Ozempic?

In clinical trials, tirzepatide (Mounjaro) was more effective than semaglutide 1 mg (Ozempic) for both A1C reduction (2.0% vs 1.9%) and weight loss (12% vs 6%). However, direct comparison with Ozempic 2 mg is limited.

How does tirzepatide cause weight loss?

Tirzepatide causes weight loss through multiple mechanisms: reducing appetite (acting on brain hunger centers), increasing fullness (slowing stomach emptying), and possibly increasing energy expenditure (GIP effect on fat metabolism).

What are the side effects of tirzepatide?

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and abdominal pain. These usually occur during dose titration and improve over time. Other side effects include decreased appetite, constipation, and injection site reactions.

Can tirzepatide be used with insulin?

Yes, tirzepatide can be used with insulin, but caution is needed as the combination increases hypoglycemia risk. The insulin dose may need to be reduced when starting tirzepatide. Close blood sugar monitoring is essential.

Sources:

American Diabetes Association. Standards of Care in Diabetes—2025. Diabetes Care 2025; 48(Suppl 1)
SURPASS-1, -2, -3, -4, -5 trials
SURMOUNT-1, -2, -3 trials
Lilly Mounjaro Information